B
8.80
-0.48 (-5.17%)
| Penutupan Terdahulu | 9.28 |
| Jumlah Dagangan | 202,084 |
| Harga / Buku (P/B) | 1.80 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -5.03 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.98% |
| Nisbah Semasa (MRQ) | 14.80 |
| Aliran Tunai Operasi (OCF TTM) | -18.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.72 M |
| Pulangan Atas Aset (ROA TTM) | -31.34% |
| Pulangan Atas Ekuiti (ROE TTM) | -48.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Benitec Biopharma Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.40 |
|
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.12% |
| % Dimiliki oleh Institusi | 85.44% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 01 Jun 2018 | - | 08 Jun 2018 | 0.002929 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2018 | 0.003 | 1 | 0.00 |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |